Current Portfolio

Companies

AMLO Biosciences

Rather than taking a passive role, we pursue an active investment strategy aimed at amplifying the positive impact of our portfolio companies. For example, our Chairman recently joined the Board of Directors of AMLO Biosciences, one of our investments focused on expanding access to early cancer screening. He guides commercialization as AMLO looks to bring its potentially life-saving diagnostic solutions to more high-risk populations in Australia, New Zealand and beyond.

With skin cancer and melanoma rates dangerously high in these countries, we believe AMLO’s innovations could have immense life-saving potential through early detection. Yet making such screening ubiquitously available requires navigating complex regulatory systems. Leveraging decades of healthcare investment experience, we are keen on leveraging time, expertise and networks to help expedite AMLO’s global expansion. Our goal is ensuring equitable delivery of AMLO’s tests to the many communities worldwide where earlier cancer diagnosis can dramatically improve survival outcomes.

Additionally, our team is actively utilizing our extensive European relationships and connections to facilitate AMLO’s vital R&D partnerships across the EU. We take an hands-on approach to linking AMLO with major cancer research hubs where we have the relationships to accelerate its product development and clinical trials. We pursue these active measures because we share AMLO’s mission – not just seeking returns, but seeking to save lives by expanding access to early screening globally.